Latest Regulatory Approval News

RTG Mining has completed a A$15.3 million tranche 2 placement, bolstering its financial position to advance the Mabilo gold and copper project and explore new opportunities.

Tempest Minerals has refined and extended the gold anomaly at its Sanity Prospect within the Yalgoo Project through denser geochemical sampling, boosting confidence in a potentially large mineralised system.

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

Havilah Resources reports significant progress on its copper-gold-cobalt projects Kalkaroo and Mutooroo, alongside promising regional exploration and strategic funding efforts.

Cavalier Resources has cleared a key technical hurdle with Raptor Capital completing due diligence on the Crawford Gold Project, paving the way for binding $11 million stream finance negotiations. The updated Pre-Feasibility Study reinforces the project's strong economic potential.

Dimerix has activated the first clinical trial site in Japan for its pivotal Phase 3 ACTION3 study targeting FSGS, triggering a significant milestone payment from its Japanese partner FUSO Pharmaceutical.

NRW Holdings’ subsidiary Primero Group has landed a $157 million contract from Rio Tinto to deliver critical infrastructure at Hope Downs in Western Australia, extending their longstanding partnership.

CZR Resources has won overwhelming shareholder approval to sell its Robe Mesa Iron Ore Project to a Rio Tinto-Mitsui joint venture for approximately A$75 million, setting the stage for a significant portfolio reshuffle.

TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.

TruScreen Group Limited has announced a NZ$3 million capital raise to fund strategic growth initiatives across Asia and Africa, alongside repaying existing debt. The raise includes a placement and share purchase plan with free attaching options, signaling confidence in its expanding cervical cancer screening programs.

Uvre has cleared a crucial regulatory hurdle in its acquisition of New Zealand’s Waitekauri Gold Project, setting the stage for new leadership and exploration activities.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.